US FDA Clears Johnson & Johnson's Single-Dose COVID Vaccine; J&J To Produce A Billion Doses By End Of YearVaccination drive.

In a major development, the United States (US)' Food and Drug Administration (FDA) has cleared the world's first single-dosage COVID-19 vaccine developed by pharmaceutical major Johnson & Johnson (J&J), reports Economic Times.

Approving the vaccine for usage, FDA said that J&J's vaccine offers strong protection against serious illness, hospitalisation need and death. It noted that a single dosage was 85 per cent protective against the most severe COVID-19 illness as per the massive study conducted across three continents.

J&J is now looking to deliver 20 million doses of the vaccine to the US by end of March, with the figures likely to soar to 100 million by the summer. A few million of these shipments are likely to begin as early as tomorrow (Monday).

Overall, J&J plans to produce a billion doses of the vaccine for global supplies by the end of the year. It is also seeking authorisation for emergency use of its vaccine in Europe and from the World Health organisation (WHO).

It should be noted that Bahrain cleared the usage of J&J's vaccine before the US on Thursday (25 February) itself.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber